Brian S. Kim, MD, MTR, has been named the Vice President and Chief Biotechnology Officer at Northwell and Head of Intellectual Asset Management at the Feinstein Institutes for Medical Research and the inaugural Robin and Jack Ross Chair in Bioelectronic Medicine and Neuroimmunology and professor in the Institute of Bioelectronic Medicine.
Dr. Kim joins the Feinstein Institutes from the Icahn School of Medicine at Mount Sinai. He has authored more than 190 peer-reviewed publications in such journals as Cell, Nature, Science, New England Journal of Medicine, and JAMA. He has been continuously funded by the National Institutes of Health since 2011 and leads the Allen Discovery Center for Neuroimmune Interactions, a $10 million multi-institutional center funded by Allen Family Philanthropies.
“Dr. Kim bridges medical research, clinical innovation, and biotechnology entrepreneurship, and will innovate the field of bioelectronic medicine,” says Kevin J. Tracey, MD, President and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research, in a news release. “As our first chief biotechnology officer, he will accelerate discoveries from our labs into useful treatments that reach patients faster.”
Dr. Kim’s research has led to significant clinical advances, including the design of pivotal clinical trials that resulted in two first-in-class US Food and Drug Administration (FDA)-approved treatments for atopic dermatitis and prurigo nodularis. As an inventor of itch-centered technologies and a holder of multiple patents, he co-founded Alys Pharmaceuticals, a clinical-stage immuno-dermatology biotech company, as well as two additional biotech companies, Neurommune Therapeutics and Attu Therapeutics, where he also serves as chair of the scientific advisory board.
His has received the Marion B. Sulzberger Award, Stephen I. Katz Lectureship, Donald Y. M. Leung Award, American Skin Association Research Achievement Award in Discovery, and the Young Dermatologist Achievement Award from the International League of Dermatological Societies. Dr. Kim has also served on the editorial boards of several prominent journals, including the Journal of Allergy and Clinical Immunology, Journal of Immunology, eLife, and Cell Reports Medicine.
“The opportunity to lead biotechnology initiatives while advancing bioelectronic medicine and neuroimmunology research represents the perfect union of my clinical, scientific, and entrepreneurial passion and expertise,” says Dr. Kim. “I’m eager to collaborate with all of the teams at the Feinstein Institutes and colleagues throughout Northwell Health to speed up the process of bringing laboratory breakthroughs into practice.”
Dr. Kim’s endowed chair is made possible by the generosity of Feinstein Institutes board vice chairman Jack Ross and his wife, Robin, assistant vice president of principal gifts at Northwell Health. In his leadership role, Dr. Kim will oversee the strategic development and management of biotechnology initiatives and intellectual property assets while continuing to advance research in bioelectronic medicine and neuroimmunology.
In addition to his research and leadership responsibilities, Dr. Kim will hold an appointment as Professor in the Department of Dermatology at Northwell Health.
“Dr. Kim’s appointment reflects our commitment to transforming bold research into better outcomes for our patients,” adds John D’Angelo, MD, Northwell’s President and CEO. “With his leadership, we can better translate breakthrough science and pioneer the future of medicine while staying grounded in our mission to produce knowledge to cure disease.”
Under the leadership of Dr. Tracey, researchers discovered the inflammatory reflex and demonstrated that the nervous system can be harnessed to control inflammation and immune responses. This work led to the first FDA-approved vagus nerve stimulation implant to treat rheumatoid arthritis in 2025, with ongoing research addressing Crohn’s disease and other inflammatory conditions. Dr. Kim will help advance this research and its translation to patients through Northwell’s new clinical Center for Bioelectronic Medicine, which brings these therapies to patients with previously treatment-resistant conditions.